Delivery Order SPE2DB22D2005-SPE2DB24FJND4
Award Date 5/30/24
Potential Completion Date 5/31/24
Potential Value $3.5K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of Ozempic, a prescription medication, to the Defense Logistics Agency (DLA). The contract has a ceiling value of $2,500.58 and an ultimate completion date of June 12, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company...
- This federal contract award is for the delivery of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml to the Defense Logistics Agency (DLA) by AmerisourceBergen Drug Corp's Corporate Office Division. The contract has a ceiling value of $6,774.52 and runs through June 25, 2024. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to deliver a range of...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml to the Defense Logistics Agency (DLA). The contract has a ceiling value of $3,544.68 and is a firm fixed-price delivery order with an ultimate completion date of October 11, 2022. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025, which...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml medication to the Defense Logistics Agency (DLA). The contract has a ceiling value of $20,898.72 and a completion date of July 10, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary vehicle...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of OZEMPIC 1 MG/DOSE (4 MG/3 ML) 3ML pharmaceutical product to the Defense Logistics Agency (DLA). The contract, valued at $2,757.27, is a Firm Fixed Price Delivery Order with a completion date of July 9, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025, which serves as the...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order valued at $53,727.38 for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml pharmaceutical products. The contract has a Firm Fixed Price pricing type and an ultimate completion date of December 2, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Ozempic, a diabetes medication, with a ceiling value of $6,473.52 and a completion date of June 11, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML to the Defense Logistics Agency (DLA). The $6,966.24 firm-fixed-price delivery order has an ultimate completion date of April 22, 2024. Amerisourcebergen holds a single-award Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company...
- This federal contract award to Amerisourcebergen Drug Corp (a major pharmaceutical distributor) is a Delivery Order valued at $1,161.08 for the supply of OZEMPIC 2 MG/DOSE (8 MG/3 ML) 3ML, placed by the Defense Logistics Agency (DLA). The contract has a period of performance through November 7, 2024 and utilizes a Firm Fixed Price pricing type. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml to the Defense Logistics Agency (DLA). The $19,276.93 firm fixed price delivery order contract has an ultimate completion date of October 30, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 with the DLA Troop Support Medical that serves as a primary vehicle for providing a comprehensive range of...
- SPE2DB22D2005Indefinite Delivery Contract
- SPE2DB22D2005-SPE2DB24FJND4Delivery Order
This contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of Ozempic, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract has a ceiling value of $3,483.24 and a completion date of May 31, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to deliver a wide range of pharmaceutical products and medical supplies to the DLA. The current award is not designated as a set-aside contract.
Generated 8/29/24, 9:26 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 5/30/24 |